UTHR

319.86

2.19% 6.87

Dopo l'orario di chiusura: 319.86

United Therapeutics Corp (UTHR)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché UTHR Giù? Forum Previsione Frazionamento azionario

Precedente Chiudi:

$312.99

Aprire:

$313.18

Volume 24 ore:

368.15K

Relative Volume:

0.89

Capitalizzazione di mercato:

$14.37B

Reddito:

$2.76B

Utile/perdita netta:

$1.11B

Rapporto P/E:

14.05

EPS:

22.77

Flusso di cassa netto:

$898.10M

1 W Prestazione:

-0.95%

1M Prestazione:

-10.71%

6M Prestazione:

-10.62%

1 anno Prestazione:

+34.45%

Intervallo 1D:

$313.18

$320.67

Intervallo di 1 settimana:

$307.64

$324.57

Portata 52W:

$221.53

$417.81

United Therapeutics Corp Stock (UTHR) Company Profile

Nome

United Therapeutics Corp

Settore

Healthcare (1167)

Industria

Biotechnology (676)

Telefono

(301) 608-9292

Indirizzo

1000 SPRING ST, SILVER SPRING, MD

Dipendente

1,305

Cinguettio

Prossima data di guadagno

2024-10-30

Ultimi documenti SEC

UTHR's Discussions on Twitter

Confronta UTHR con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
UTHR United Therapeutics Corp	319.86	14.37B	2.76B	1.11B	898.10M	22.77
VRTX Vertex Pharmaceuticals Inc	511.74	131.41B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	661.00	72.26B	14.20B	4.41B	3.54B	38.28
ALNY Alnylam Pharmaceuticals Inc	290.70	37.63B	2.25B	-278.16M	-42.59M	-2.17
ARGX Argen X Se Adr	607.95	37.08B	2.19B	833.04M	-1.28B	12.71
ONC Beigene Ltd Adr	253.20	27.23B	3.81B	-644.79M	-669.77M	-6.24

United Therapeutics Corp Stock (UTHR) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2024-07-11	Downgrade	Morgan Stanley	Overweight → Equal-Weight
2024-02-12	Aggiornamento	Goldman	Sell → Neutral
2024-02-05	Iniziato	Leerink Partners	Outperform
2023-12-08	Iniziato	Wells Fargo	Overweight
2022-12-06	Iniziato	UBS	Buy
2022-12-05	Iniziato	Goldman	Sell
2022-10-11	Iniziato	Morgan Stanley	Overweight
2022-09-20	Reiterato	BofA Securities	Underperform
2022-09-19	Ripresa	Wedbush	Outperform
2022-02-11	Iniziato	BTIG Research	Neutral
2021-07-14	Aggiornamento	Argus	Hold → Buy
2021-04-26	Ripresa	Credit Suisse	Outperform
2021-02-01	Aggiornamento	H.C. Wainwright	Neutral → Buy
2020-09-14	Ripresa	JP Morgan	Overweight
2020-06-25	Reiterato	H.C. Wainwright	Neutral
2020-03-10	Aggiornamento	Jefferies	Hold → Buy
2020-02-27	Aggiornamento	Cowen	Market Perform → Outperform
2020-01-31	Aggiornamento	JP Morgan	Neutral → Overweight
2019-12-03	Iniziato	BofA/Merrill	Underperform
2019-08-01	Aggiornamento	Jefferies	Underperform → Hold
2019-08-01	Aggiornamento	Ladenburg Thalmann	Neutral → Buy
2019-07-01	Aggiornamento	Credit Suisse	Neutral → Outperform
2019-05-17	Aggiornamento	UBS	Sell → Neutral
2019-05-09	Aggiornamento	Credit Suisse	Underperform → Neutral
2018-10-12	Aggiornamento	Standpoint Research	Hold → Buy
2018-08-08	Downgrade	Credit Suisse	Neutral → Underperform
2018-04-03	Aggiornamento	Credit Suisse	Underperform → Neutral
2018-02-22	Reiterato	Barclays	Underweight
2018-01-18	Ripresa	Credit Suisse	Underperform
2017-12-27	Reiterato	Wedbush	Outperform
2017-04-27	Reiterato	Wedbush	Outperform
2017-03-30	Iniziato	UBS	Sell
2017-03-16	Iniziato	Credit Suisse	Underperform

Mostra tutto

United Therapeutics Corp Borsa (UTHR) Ultime notizie

Mar 20, 2025

United Therapeutics director sells $1.55 million in stock By Investing.com - Investing.com Canada

Mar 20, 2025

United Therapeutics director sells $1.55 million in stock - Investing.com India

Mar 20, 2025

Market Turbulence? These 20 Stocks Boast a Perfect Piotroski Score and 40%+ Upside - Investing.com

Mar 20, 2025

Mar 19, 2025

United Therapeutics price target lowered to $314 from $328 at BofA - TipRanks

Mar 19, 2025

Exosome Therapy Market Market Is Booming Worldwide 2025-2032 | - openPR

Mar 19, 2025

Mar 14, 2025

Is United Therapeutics Corporation (UTHR) the Best Healthcare Stock For Long-Term Investment? - Insider Monkey

Mar 14, 2025

Mar 12, 2025

United Therapeutics president Michael Benkowitz sells $640k in stock By Investing.com - Investing.com Australia

Mar 12, 2025

Mar 11, 2025

For patients needing transplants, hope arrives on tiny hooves - The Spokesman Review

Mar 11, 2025

United Therapeutics president Michael Benkowitz sells $640k in stock - Investing.com

Mar 11, 2025

Mar 04, 2025

What Will United Therapeutics Reveal at the Leerink Conference? Key Details for Investors - StockTitan

Mar 04, 2025

Mar 03, 2025

Top Executives Cash In on United Therapeutics Stock! - TipRanks

Mar 03, 2025

Ray Kurzweil Sells 15,000 Shares of United Therapeutics Corp - GuruFocus.com

Mar 03, 2025

United Therapeutics director Thompson sells $795,837 in stock By Investing.com - Investing.com Canada

Mar 03, 2025

United Therapeutics director Thompson sells $795,837 in stock - Investing.com India

Mar 03, 2025

Silver Spring's United Therapeutics to Begin Clinical Study of Groundbreaking UKidney™ (Pig Organ) Transplant - The MoCoShow

Mar 03, 2025

Q2 EPS Estimate for United Therapeutics Lowered by Analyst - Defense World

Mar 03, 2025

Mar 01, 2025

Oppenheimer Asset Management Inc. Sells 6,988 Shares of United Therapeutics Co. (NASDAQ:UTHR) - MarketBeat

Mar 01, 2025

Bank of New York Mellon Corp Sells 1,693 Shares of United Therapeutics Co. (NASDAQ:UTHR) - MarketBeat

Mar 01, 2025

United Therapeutics Receives FDA Approval for Pig Organ Clinical Trials - Source of the Spring

Mar 01, 2025

United Therapeutics (NASDAQ:UTHR) Earns “Buy” Rating from HC Wainwright - Defense World

Mar 01, 2025

United Therapeutics Co. (NASDAQ:UTHR) Shares Sold by New York State Common Retirement Fund - MarketBeat

Mar 01, 2025

Feb 28, 2025

Weil Company Inc. Has $449,000 Position in United Therapeutics Co. (NASDAQ:UTHR) - MarketBeat

Feb 28, 2025

United Therapeutics (NASDAQ:UTHR) Releases Earnings Results, Beats Expectations By $0.09 EPS - MarketBeat

Feb 28, 2025

United Therapeutics (NASDAQ:UTHR) Shares Gap Down Following Insider Selling - MarketBeat

Feb 28, 2025

United Therapeutics Co. (NASDAQ:UTHR) Stock Position Boosted by Fjarde AP Fonden Fourth Swedish National Pension Fund - MarketBeat

Feb 28, 2025

United Therapeutics (NASDAQ:UTHR) Releases Quarterly Earnings Results, Beats Expectations By $0.09 EPS - MarketBeat

Feb 28, 2025

Los Angeles Capital Management LLC Has $36.55 Million Stake in United Therapeutics Co. (NASDAQ:UTHR) - MarketBeat

Feb 28, 2025

Truist Financial Corp Sells 2,920 Shares of United Therapeutics Co. (NASDAQ:UTHR) - MarketBeat

Feb 28, 2025

United Therapeutics Co. (NASDAQ:UTHR) COO Michael Benkowitz Sells 10,000 Shares - MarketBeat

Feb 28, 2025

Atria Wealth Solutions Inc. Invests $412,000 in United Therapeutics Co. (NASDAQ:UTHR) - Defense World

Feb 28, 2025

United Therapeutics price target lowered to $420 from $430 at Leerink - Yahoo Finance

Feb 28, 2025

Lung transplant technology collaboration between Mayo Clinic Florida and United Therapeutics - Florida Trend

Feb 28, 2025

Feb 27, 2025

United Therapeutics Corp. Reports Record Revenue and Growth - TipRanks

Feb 27, 2025

United Therapeutics Corp. to Host Earnings Call - ACCESS Newswire

Feb 27, 2025

United Therapeutics Reports Record Revenue in Q4 2024, Advances Strategic Growth - HPBL

Feb 27, 2025

United Therapeutics Corporation (NASDAQ:UTHR) Q4 2024 Earnings Call Transcript - Insider Monkey

Feb 27, 2025

Goldman Sachs cuts United Therapeutics stock target to $293 By Investing.com - Investing.com Australia

Feb 27, 2025

Goldman Sachs cuts United Therapeutics stock target to $293 - Investing.com

Feb 27, 2025

United Therapeutics: Q4 Earnings Snapshot - Thehour.com

Feb 27, 2025